Accurate Risk Assessment of Patients with Pathologic T3aN0M0 Renal Cell Carcinoma

Jong Jin Oh1,2, Jung Keun Lee1, Byung Do Song1, Hakmin Lee1, Sangchul Lee1, Seok-Soo Byun1,2, Sang Eun Lee1 & Sung Kyu Hong1,2

To develop a more precise risk-stratification system by investigating the prognostic impact of tumor growth within fatty tissues surrounding the kidney and/or renal vein. We conducted a retrospective review of the medical records of 211 patients with a pathologic diagnosis of T3aN0M0 RCC among 4,483 renal cell carcinoma (RCC) patients from February 1988 to December 2015 according to the number of T3a pathologies—extrarenal fat invasion (EFI) and/or renal venous invasion (RVI). During a mean follow-up duration of 38.8 months, the patients with both pathologies (EFI + RVI) had lower recurrence free survival (RFS) rate than those with only a single pathology (p = 0.001). Using multivariable Cox regression analysis, the presence of both factors was shown to be an independent predictor of RFS (HR = 1.964, p = 0.032); cancer specific survival rate was not different among patients with EFI and/or RVI. Patients with pathologic T3aN0M0 RCC presenting with both EFI and RVI were at an increased risk of recurrence following nephrectomy. Therefore, pathologic T3a RCC could be sub-divided into those with favorable and unfavorable disease according to presence of EFI and/or RVI pathologies.

Renal cell carcinoma (RCC) is the third most common urologic cancer in the world, making up roughly 3% of all human cancers1. Studies have shown that 20–30% RCC recur after surgical treatment, thus highlighting the importance of: i) using prognosticators (eg, pathological staging) when developing a treatment plan and ii) close monitoring during and following treatment2–4. The 2002 RCC Tumor-Node-Metastasis (TNM) staging system defined T3 RCC as a tumor that extends to fat, adrenal or major vein. In 2009 however, this system was updated to better differentiate and improve prognosis of T3 tumors6–8. In the 2009 version, renal vein invasion was down-staged from T3b to T3a and adrenal invasion was up-staged from T3a to T4 or M16. In the current staging system, T3a RCC is defined as a tumor with extra-renal fat invasion (EFI) (perinephric or sinus fat invasion) and renal venous invasion (RVI) (renal vein or its segmental muscle containing branch)9. The limited data available comparing the prognostic significance of EFI and/or RVI are inconsistent10,11. For instance, some studies have suggest a significant impact of RVI on clinical outcome, while others have reported no prognostic value to the presence of tumor thrombus12. Other studies show that RCC with both EFI and RVI have higher recurrence rates than those with only EFI or RVI10.

Currently, a T3a RCC tumor may have EFI and/or RVI and the prognostic significance of these characteristics is unclear. We hypothesize that T3 tumors with EFI and/or RVI are more aggressive than those with only EFI or RVI and have designed the current research study to compare the impact of these features in non-metastatic T3a tumors (ie, prognosis, survival).

Materials and Methods
An approval of this study was obtained from institutional review board approval (B-1712/381-108, and written informed consent was acquired from all patients before the inclusion to the research.

Patient selection. After receiving institutional review board approval, we reviewed the data of all patients (n = 4,483) who underwent a partial or radical nephrectomy for RCC between February 1988 and December 2015 from two tertiary hospital (Seoul National University Hospital and Seoul National University Bundang Hospital). Among them, we identified 211 patients with T3aN0M0 RCC for this analysis.

1Department of Urology, Seoul National University Bundang Hospital, Seongnam-si, South Korea. 2Department of Urology, Seoul National University College of Medicine, Seoul, South Korea. Correspondence and requests for materials should be addressed to S.K.H. (email: skhong@snubh.org)
Data collection protocol. Postoperative pathologic tumor stages and grades were determined in accordance with the seventh AJCC TNM staging\textsuperscript{13} and Fuhrman grading system\textsuperscript{14}, respectively. Histological subtypes of RCC were assigned in accordance with the WHO classification system\textsuperscript{15}. We evaluated the following clinical and pathologic features: age at surgery, gender, body mass index, Eastern Cooperative Oncology Group performance (ECOG) status, surgery type (partial nephrectomy [PN] or radical nephrectomy [RN]), tumor location, tumor size, histologic subtype (clear cell, papillary, chromophobe and unclassified), Fuhrman nuclear grade, capsular invasion, presence of necrosis, angiolymphatic invasion, perineural invasion and sarcomatoid differentiation. Additionally, T3a tumors were classified as: i) isolated EFI, isolated RVI, or iii) EFI and RVI.

Follow up protocol. After nephrectomy, all patients were followed up according to the SNU protocol. Symptom assessments, routine blood tests, chest x-rays and kidney/bladder Computed tomography (CT) scans were conducted every 3 months for the first 2 years. Following year 2, the same battery of tests were conducted every 6 months for 2 years followed by annual follow ups as necessary.

Statistical analysis. Comparisons were conducted across the T3a patient classifications (ie, EFI, RVI, and EFI + RVI). Another group analysis was performed according to the number of cause of pT3a (ie, isolated EFI or RVI, and EFI + RVI). Analyses were performed using SPSS for Windows, version 22.0 (SPSS Inc., Chicago,IL, USA). Fisher’s exact and Pearson chi-squared tests were performed to compare clinical and pathological features among groups. Differences in variables with a continuous distribution across dichotomous categories were assessed using the Mann –Whitney U-test. A P value of <0.05 was considered statistically significant.

Recurrence was defined as radiologically verified metastasis or local disease recurrence during the study period. Recurrence-free survival (RFS) was defined as the interval between the primary surgery and the last follow-up visit and the absence of disease recurrence or progression. Cancer-specific survival (CSS) was defined as the interval between the primary surgery and the last follow-up visit or RCC related death. The RFS and CSS in each group were estimated using Kaplan–Meier methods and the log-rank test was applied to compare survival curves. Univariate and Multivariate Cox proportional hazard models were used to verify predictors of RFS and CSS.

Results

Baseline characteristics of pT3a RCC patients. The clinical and pathological characteristics of 211 T3aN0M0 RCC patients who underwent nephrectomy are summarized in Table 1. This study included 158 male patients (74.9%) and 53 female patients (25.1%). The median age (IQR) was 60 years old (52–69), mean BMI (IQR) was 23.9 (22.3–26.2) and most patients had ECOG performance status 0–1 (95.3%). Among 211 patients, 26 patients (12.3%) underwent PN. Median tumor size (IQR) was 6.8 centimeter (4.9–9.4), and 81.5% of tumors were classified as clear cell type. EFI was present in 173 patients (82.0%) and RVI was present in 84 (39.8%); 47 patients had EFI and RVI (23.3%). Total of 124 (58.8%) patients had only EFI and 40 (19.0%) patients had only RVI as cause of pT3a, respectively. The comparison of baseline characteristics according to groups were shown in Table 1.

Recurrence-free survival. During a mean follow-up of 38.8 months (median 26.0 months), radiologic recurrence was observed in 42 patients (19.9%). The site of recurrence was recorded as renal fossa (28/42, 66.6%), lymph node (8/42, 19.0%) and lung (4/42, 9.5%). RFS was significantly lower in EFI + RVI group than either EFI only or RVI only groups (Fig. 1A, log rank test = 0.008 or 0.010, respectively). According to the number of parameters leading to T3a classification, which Group B (EFI + RVI) had a significantly lower RFS rate than Group A (EFI only + RVI only) (Fig. 1B, p = 0.002). Seven-year RFS rates were calculated as 57.8% in Group A and 26.4% in Group B.

As shown in Table 2, sex, tumor size, tumor necrosis, perineural invasion, angiolymphatic invasion, sarcomatoid differentiation and having both EFI and RVI (Group B) were significant factors in univariate Cox proportional hazard analysis and predictive of tumor recurrence. Using a multivariate analysis, sex, tumor size, tumor necrosis, and having both EFI and RVI (Group B) were shown to be significant factors.

Cancer-specific survival. During follow-up, 23 patients died due to RCC. CSS free survival was lower in the EFI + RVI group than either EFI-only or RVI-only group, however this difference was not statistically significant (Fig. 2, log rank test = 0.625, 0.882, respectively). Using a multivariate Cox proportional hazard analysis, tumor size was shown to be a significant factor in determining CSS among T3a RCC patients who underwent nephrectomy (HR = 1.133, 95% CI: 1.040–1.234, p = 0.004) (Table 3). Another factors (positive surgical margin and presence of tumor necrosis) were significant factors to predict cancer specific survival (HR = 19.864, p < 0.001 and HR = 4.238, p = 0.025, respectively).

Discussion

In this analysis, we reviewed 211 T3aN0M0 RCC patients who underwent surgical treatment, and stratified patients according to the cause of their RCC classification as T3a; the 173 EFI (82.0%) and 84 RVI (39.8%) patients had similar RFS rates during a median follow-up of 26.0 months. However, patients with both EFI and RVI (n = 47, 23.3%) had a significantly lower RFS rate than patients who had only one factor. Despite of no significance to CSS, the patients who had EFI and RVI had more aggressive feature among T3a RCC patients.

Da Costa et al\textsuperscript{16} who reported similar results to ours stratified 46 T3a RCC patients into one of 3 groups: i) EFI only (24 [52.1%]), ii) RVI only (11 [23.9%]), and iii) EFI and RVI (11 [23.9%]). According to their study, patients with both pathologies had poorer RFS rate (roughly 22%) than patients with only one factor. In our study, using larger cohorts, patients with both pathologies had a PFS of 26.4% at 7 years.
According to the current TNM staging system, EFI and RVI can each lead to inclusion in the same stage – (T3a) regardless of whether one or both of these pathologies (EFI or RVI) are present. However, several previous studies have shown that patients with EFI and RVI had poorer outcomes than those with only one (EFI or RVI) 10,16–18. A recent European multi-center study17, validated the latest edition of the TNM (2009), evaluating 503 cases of T3a stage RCC and noting significantly lower survival rates in patients with concomitant EFI and RVI vs those with the single pathologies. Margulis et al.18 confirmed these results by analyzing 419 patients treated for pT3a stage RCC; poorer survival rates were observed in patients with EFI + RVI compared to patients with either pathology alone.

Our results indicate a significant difference in RFS among groups A (single pathology) and B (both pathologies), however we did not observe a significant difference among the CSS of the two groups. The difference between our study and previous studies is that we excluded patients who had lymph node invasion (LNI)10,16. The previous study showed that patients who had LNI had higher rates of LNI. According to the Da Costa group 10, patients

Table 1. Clinical and pathological characteristics of the patients with pT3a renal cell carcinoma according to cause of pathologic T3a. IQR; interquartile range, ECOG; Eastern Cooperative Oncology Group, EFI; isolated extracapsular fat invasion, RVI; isolated renal venous invasion.

| Variables                        | Total | EFI only | RVI only | EFI + RVI | p-value |
|----------------------------------|-------|----------|----------|-----------|---------|
| No. patients                     | 211   | 124      | 40       | 47        |         |
| Median age (year)(IQR)           | 60.0 (52–69) | 58.5 (50.0–69.0) | 62.8 (54.0–71.0) | 62.7 (56.0–69.0) | 0.041   |
| Female (%)                       | 55 (25.1) | 30 (24.2) | 13 (32.5) | 10 (21.3) | 0.509   |
| Median body mass index (kg/m²)(IQR)| 23.9 (22.3–26.2) | 24.4 (22.6–26.3) | 24.5 (22.1–26.3) | 24.0 (21.7–26.2) | 0.690   |
| ECOG performance status (%)      |       |          |          |           |         |
| 0–1                              | 201 (95.3) | 120 (96.8) | 38 (95.0) | 44 (93.6) | 0.475   |
| 2–3                              | 10 (4.7)  | 4 (3.2)  | 2 (5.0)  | 3 (6.4)   |         |
| Partial nephrectomy (%)          | 26 (12.3) | 22 (17.7) | 1 (2.5)  | 3 (6.3)   | 0.012   |
| Median pathologic tumor diameter (cm)(IQR) | 6.8 (4.9–9.4) | 6.5 (4.5–9.5) | 7.2 (4.5–9.1) | 7.0 (5.0–9.4) | 0.600   |
| Histological type (%)            |       |          |          |           | 0.489   |
| Clear cell                       | 172 (81.5) | 100 (80.6) | 34 (85.0) | 38 (80.9) |         |
| Papillary                        | 15 (7.1)  | 10 (8.1) | 1 (2.5)  | 4 (8.5)   |         |
| Chromophobe                      | 18 (8.5)  | 11 (8.9) | 3 (7.5)  | 4 (8.5)   |         |
| Others                           | 6 (2.9)  | 3 (2.4)  | 2 (5.0)  | 1 (2.1)   |         |
| Fuhrman grade (%)                |       |          |          |           | 0.195   |
| 1–2                              | 45 (20.3) | 31 (25.0) | 4 (10.0) | 9 (19.1)  |         |
| 3–4                              | 166 (78.7)| 93 (75.0)| 36 (90.0)| 38 (80.9) |         |
| Positive surgical margin (%)     | 4 (1.9)  | 2 (1.6)  | 1 (2.5)  | 1 (2.1)   | 0.939   |
| Capsular invasion (%)            | 152 (72.0)| 102 (82.3) | 12 (30.0) | 38 (80.9) | <0.001  |
| Necrosis (%)                     | 103 (48.8)| 59 (47.6)| 18 (45.0)| 26 (55.3)| 0.541   |
| Angiolympathic invasion (%)      | 33 (15.6)| 10 (8.1) | 9 (22.5) | 14 (29.8) | 0.004   |
| Perineural invasion (%)          | 6 (2.8)  | 3 (2.4)  | 1 (2.5)  | 2 (4.3)   | 0.804   |
| Sarcomatoid differentiation (%)  | 26 (12.3)| 11 (8.9) | 3 (7.5)  | 12 (25.5) | 0.007   |

According to the current TNM staging system, EFI and RVI can each lead to inclusion in the same stage – (T3a) regardless of whether one or both of these pathologies (EFI or RVI) are present. However, several previous studies have shown that patients with EFI and RVI had poorer outcomes than those with only one (EFI or RVI)10,16–18. A recent European multi-center study17, validated the latest edition of the TNM (2009), evaluating 503 cases of T3a stage RCC and noting significantly lower survival rates in patients with concomitant EFI and RVI vs those with the single pathologies. Margulis et al.18 confirmed these results by analyzing 419 patients treated for pT3a stage RCC; poorer survival rates were observed in patients with EFI + RVI compared to patients with either pathology alone. Our results indicate a significant difference in RFS among groups A (single pathology) and B (both pathologies), however we did not observe a significant difference among the CSS of the two groups. The difference between our study and previous studies is that we excluded patients who had lymph node invasion (LNI)10,16. The previous study showed that patients who had EFI and RVI had higher rates of LNI. According to the Da Costa group10, patients
with both pathologies had much higher rates of LNI than those with a single pathology only. A study by Chen et al.2 also showed no difference between RVI and/or EFI among T3N0M0 patients. Findings published by Abel et al.19, showed no difference in CSS according to the presence of RVI with or without EFI. Differences in exclusion criteria showed the somewhat different CSS results between RVI and EFI among our results and previous reported results.

In our results, EFI-only and RVI-only patients had similar RFS and CSS rates. Baccos et al.11 reported that the CSS was similar in RVI-only and EFI-only patients, Novara et al.17, in a large multi-institutional study, showed that an RVI-only group had a better prognosis than the fat-invasion group. In contrast, Jung et al.20 reported that a group of RVI-only patients had lower 2-year and 5-year survival rates than the fat invasion group. Park et al.16 showed that RVI-only patients had significantly lower RFS and CSS than EFI among T3aN0M0 patients after nephrectomy. Therefore, this issue is still controversial and future prospective studies may be required to confirm the results of these studies.

Another interesting issue in this study was shown in multivaratie analysis to predict RFS and CSS. Regardless of the number of factors of pT3a, tumor diameter and tumor necrosis were significant factors to RFS and CSS, respectively. A previous reports also showed in their study among pT3a RCC patients the importance of tumor size in pT3a, HR to recurrence was 1.125 (p < 0.001)21 and HR to CSS was 2.506 (p = 0.011)2, it was same result in our study. And another study about tumor necrosis was similar results to our study, they emphasized the significance of tumor necrosis to prognosis in RCC patients22,23.

### Table 2.

| Variables                        | HR (95% CI) | p-value | HR (95% CI) | p-value |
|----------------------------------|------------|---------|------------|---------|
| **Univariate analysis**          |            |         |            |         |
| Age                              | 1.005 (0.984–1.027) | 0.650   |            |         |
| Female                           | 1.905 (1.131–3.207) | 0.015   | 2.222 (1.291–3.825) | 0.003  |
| Body mass index                  | 0.929 (0.851–1.015) | 0.101   |            |         |
| ECOG performance status          | 2.326 (0.937–6.463) | 0.105   |            |         |
| Tumor diameter                   | 1.163 (1.103–1.227) | <0.001  | 1.107 (1.047–1.170) | <0.001  |
| Surgical methods (RN vs PN)      | 0.634 (0.273–1.474) | 0.290   |            |         |
| Surgical margin positive         | 0.955 (0.475–1.919) | 0.897   |            |         |
| Histologic type (clear cell vs.) | 1.272 (0.700–2.313) | 0.430   |            |         |
| Fuhrman grade (1–2 vs 3–4)       | 1.624 (0.859–3.072) | 0.136   |            |         |
| Extra-renal fat invasion         | 5.154 (4.264–6.230) | <0.001  |            |         |
| Renal venous invasion            | 6.175 (5.050–7.550) | <0.001  |            |         |
| pT3a factor (2 vs 1)             | 2.254 (1.319–3.850) | 0.003   | 1.961 (1.059–3.632) | 0.032  |
| Capsular invasion                | 1.099 (0.624–1.935) | 0.744   |            |         |
| Necrosis                         | 3.100 (2.777–3.461) | <0.001  | 3.163 (1.760–5.684) | <0.001  |
| Perineural invasion              | 7.681 (4.091–14.420) | <0.001  | 1.795 (0.487–6.624) | 0.380  |
| Angiolymphatic invasion          | 6.356 (5.004–8.074) | <0.001  | 1.923 (0.985–3.753) | 0.055  |
| Sarcomatoid differentiation      | 1.412 (1.305–1.529) | <0.001  | 1.409 (0.694–2.863) | 0.343  |

**Table 2.** Uni- and Multi-variable Cox-regression analyses on recurrence free survival. HR; hazard ratio, CI; confidence interval, ECOG; Eastern Cooperative Oncology Group, RN; radical nephrectomy, PN; partial nephrectomy.

### Figure 2.

Cancer specific survival of 211 patients with T3aN0M0 renal cell carcinoma patients according to presence of extrarenal fat invasion (EFI) and/or renal venous invasion (RVI). Comparison by Kaplan-meier analysis showed each group (EFI vs. RVI vs. both) (A), comparison by the number of pathologis (EFI/RVI) – isolated EFI or RVI vs. both group (B).
There were several limitations, in our study. Firstly, our study was a retrospective chart review. Secondly, we could not differentiate between EFI into perinephric fat invasion and sinus fat invasion. However, most studies which compare perinephric fat invasion and sinus fat invasion have reported similar results between two groups. Mouracade et al.\(^4\) showed, in their analysis of 143 T3a RCC patients, sinus fat invasion and perinephric fat invasion had similar prognostic values. Poon et al.\(^5\) reported that sinus fat invasion was not a predictor of CSS. Therefore, our inability to stratify patients with EFI into perinephric fat invasion and sinus fat invasion groups could be significant. Despite a relatively long follow up duration (mean of roughly 40 months), only 10% patients died from RCC, therefore CSS analysis was limited by the small sample size. More studies with a longer follow up and more patients from multiple centers could overcome this limitation.

In conclusion, among T3aN0M0 RCC patients, those who had both EFI and RVI had poor PFS rates than patients with only one pathology (ie, EFI or RVI). Therefore, following surgery, T3a patients with EFI and RVI should be more closely followed up than other T3a RCC patients.

### References

1. DeSantis, C. E. et al. Cancer treatment and survivorship statistics, 2014. *CA Cancer J Clin* 64, 252–271, https://doi.org/10.3322/caac.21235 (2014).
2. Chen, L. et al. Influence of tumor size on oncological outcomes of pathological T3aN0M0 renal cell carcinoma treated by radical nephrectomy. *Plos one* 12, e0173953, https://doi.org/10.1371/journal.pone.0173953 (2017).
3. Crispin, P. L. et al. Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. *Eur Urol* 59, 18–23, https://doi.org/10.1016/j.euro.2010.08.042 (2011).
4. Ljungberg, B. et al. EAU guidelines on renal cell carcinoma: 2014 update. *Eur Urol* 67, 913–924, https://doi.org/10.1016/j.eururo.2015.01.005 (2015).
5. MacLennan, S. et al. Systematic review of oncological outcomes following surgical management of localised renal cancer. *Eur Urol* 61, 972–993, https://doi.org/10.1016/j.euro.2012.02.039 (2012).
6. Zhang, Z. et al. The Difference in Prognosis between Renal Sinus Fat and Perinephric Fat Invasion for pT3a Renal Cell Carcinoma: A Meta-Analysis. *PLoS One* 11, e0149420, https://doi.org/10.1371/journal.pone.0149420 (2016).
7. Kim, S. P. et al. Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort. *J Urol* 185, 2035–2039, https://doi.org/10.1016/j.juro.2011.02.059 (2011).
8. Delaunay, B. Advances and controversies in grading and staging of renal cell carcinoma. *Mod Pathol* 22(Suppl 2), S24–36, https://doi.org/10.1038/modpathol.2008.183 (2009).
9. Brookman-May, S. D. et al. Evaluation of the prognostic significance of perirenal fat invasion and tumor size in patients with pT1–pT3a localized renal cell carcinoma in a comprehensive multicenter study of the CORONA project. Can we improve prognostic discrimination for patients with stage pT3a tumors? *Eur Urol* 67, 943–951, https://doi.org/10.1016/j.eururo.2014.11.055 (2015).
10. da Costa, W. H. et al. Impact of renal vein invasion and fat invasion in pT3a renal cell carcinoma. *PLoS One* 10, 544–548, 10.1371/journal.pone.0137953 (2015).
11. Baccos, A. et al. Differing risk of cancer death among patients with pathologic T3a renal cell carcinoma: identification of risk categories according to fat infiltration and renal vein thrombosis. *Clin Genitourin Cancer* 11, 451–457, https://doi.org/10.1016/j.clgc.2013.05.006 (2013).
12. Pouliot, F., Shuch, B., Larochelle, J. C., Pantuck, A. & Bellegard, A. S. Contemporary management of renal tumors with venous tumor thrombus. *J Urol* 184, 833–841; quiz 1235, https://doi.org/10.1016/j.juro.2010.04.071 (2010).
13. Edge, S. B. & Compton, C. C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol* 17, 1471–1474, https://doi.org/10.1245/s10434-010-0985-x (2010).
14. Fuhrman, S. A., Lasky, L. C. & Limas, C. Prognostic significance of morphologic parameters in renal cell carcinoma. *Am J Surg Pathol* 6, 655–663 (1982).

| Variables                        | Univariate analysis HR (95% CI) | p-value | Multivariate analysis HR (95% CI) | p-value |
|----------------------------------|---------------------------------|---------|----------------------------------|---------|
| Age                              | 0.980(0.945–1.017)              | 0.290   |                                  |         |
| Female                           | 1.037 (0.403–2.669)             | 0.940   |                                  |         |
| Body mass index                  | 0.973 (0.841–1.125)             | 0.708   |                                  |         |
| ECOG performance status          | 2.660(0.610–11.594)             | 0.193   |                                  |         |
| Tumor diameter                   | 1.169 (1.092–1.252)             | <0.001  | 1.133(1.040–1.234)                | 0.004   |
| Surgical methods (RN vs PN)      | 0.368 (0.048–2.748)             | 0.329   |                                  |         |
| Surgical margin positive         | 7.784 (1.758–34.457)            | 0.007   | 19.864(3.803–103.749)            | <0.001  |
| Histologic type (clear cell vs.) | 1.346(0.492–3.684)              | 0.563   |                                  |         |
| Fuhrman grade (1–2 vs 3–4)       | 2.216 (0.736–6.672)             | 0.157   |                                  |         |
| Extra-renal fat invasion         | 1.033 (0.323–4.605)             | 0.966   |                                  |         |
| Renal vein invasion              | 1.701 (0.960–4.197)             | 0.249   |                                  |         |
| pT3a factor (2 vs 1)             | 1.901 (0.735–4.918)             | 0.185   | 1.907(1.107–12.301)               | 0.201   |
| Capsular invasion                | 0.525 (0.224–1.229)             | 0.138   |                                  |         |
| Necrosis                         | 4.760 (1.601–14.148)            | 0.005   | 4.238(1.201–14.957)               | 0.025   |
| Angiolymphatic invasion          | 2.166 (0.777–6.035)             | 0.139   |                                  |         |
| Sarcomatoid differentiation      | 3.778 (1.232–11.583)            | 0.020   | 1.580(0.434–5.747)                | 0.487   |

Table 3. Uni- and Multi-variable Cox-regression analyses on cancer specific survival. HR; hazard ratio, CI; confidence interval, ECOG; Eastern Cooperative Oncology Group, RN; radical nephrectomy, PN; partial nephrectomy.
15. Lopez-Beltran, A., Scarpelli, M., Montironi, R. & Kirkali, Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol 49, 798–805, https://doi.org/10.1016/j.eururo.2005.11.035 (2006).

16. Park, M. et al. Prognostic heterogeneity in T3aN0M0 renal cell carcinoma according to the site of invasion. Urol Oncol 35, 458.e417–458.e422, https://doi.org/10.1016/j.urolonc.2016.05.019 (2017).

17. Novara, G. et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol 58, 588–595, https://doi.org/10.1016/j.eururo.2010.07.006 (2010).

18. Margulis, V. et al. Redefining pT3 renal cell carcinoma in the modern era: a proposal for a revision of the current TNM primary tumor classification system. Cancer 109, 2439–2444, https://doi.org/10.1002/cncr.22713 (2007).

19. Abel, E. J., Margulis, V. & Bauman, T. M. Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis. BJU int 117, E87–94, https://doi.org/10.1111/bju.13268 (2016).

20. Jung, S. J., Ro, J. Y., Truong, L. D., Ayala, A. G. & Shen, S. S. Reappraisal of T3N0/NxM0 renal cell carcinoma: significance of extent of fat invasion, renal vein invasion, and adrenal invasion. Hum Pathol 39, 1689–1694, https://doi.org/10.1016/j.humpath.2008.04.011 (2008).

21. Oh, J. J. et al. Partial nephrectomy versus radical nephrectomy for non-metastatic pathological T3a renal cell carcinoma: a multi-institutional comparative analysis. Int J Urol 21, 352–357, https://doi.org/10.1111/iju.12283 (2014).

22. Khor, L. Y. et al. Tumor Necrosis Adds Prognostically Significant Information to Grade in Clear Cell Renal Cell Carcinoma: A Study of 842 Consecutive Cases From a Single Institution. Am J Surg Pathol. 40, 1224–1231, https://doi.org/10.1097/PAS.0000000000000690 (2016).

23. Pichler, M. Trends of stage, grade, histology and tumour necrosis in renal cell carcinoma in a European centre surgical series from 1984 to 2010. J Clin Pathol. 65, 721–724, https://doi.org/10.1136/jclinpath-2012-200797 (2012).

24. Mouracade, P. et al. Perinephric and Sinus Fat Invasion in Stage pT3a Tumors Managed by Partial Nephrectomy. Clin Genitourin Cancer, https://doi.org/10.1016/j.clgc.2017.07.019 (2017).

25. Poon, S. A., Gonzalez, J. R., Benson, M. C. & McKiernan, J. M. Invasion of renal sinus fat is not an independent predictor of survival in pT3a renal cell carcinoma. BJU Int 103, 1622–1625, https://doi.org/10.1111/j.1464-410X.2008.08239.x (2009).

Author Contributions

Study concept and design: Sung Kyu Hong. Acquisition of data: Jong Jin Oh, Jung Keun Lee, yung Do Song, Hakmin Lee, Sangchul Lee, Seok-soo Byun, Sang Eun Lee. Analysis and interpretation of data: Jong Jin Oh, Jung Keun Lee. Drafting of the manuscript: Jong Jin Oh. Critical revision of the manuscript for important intellectual content: Sung Kyu Hong. Statistical analysis: Jong Jin Oh. Obtaining funding: N/A. Administrative, technical, or material support: Jong Jin Oh. Supervision: Sung Kyu Hong. Other (specify): None.

Additional Information

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018